The EORTC strategy in the treatment of Hodgkin's lymphoma
The EORTC strategy in the treatment of Hodgkin's lymphoma
The EORTC strategy in the treatment of Hodgkin's lymphoma
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Eghbali et al.<br />
Group trial no. 20884. Eur J Haematol 2004;73(Suppl.<br />
65):42, A01.<br />
28. Hasenclever D, Diehl V. A prognostic score for advanced<br />
Hodgk<strong>in</strong>’s disease. N Engl J Med 1998;339:1506–1514.<br />
29. Bonadonna G, Zucalli R, Monfard<strong>in</strong>i S, De Lena M,<br />
Uslenghi C. Comb<strong>in</strong>ation <strong>of</strong> chemo<strong>the</strong>rapy <strong>of</strong> Hodgk<strong>in</strong>’s<br />
disease with adriamyc<strong>in</strong>, bleomyc<strong>in</strong>, v<strong>in</strong>blast<strong>in</strong>e and<br />
imidazole carboxamide versus MOPP. Cancer<br />
1975;36:252–259.<br />
30. Carde P. Les essais concernant la maladie de Hodgk<strong>in</strong><br />
mene´s par l’Organisation Europe´enne de Recherche et de<br />
Traitement sur le Cancer (OERTC): leur impact sur les<br />
progre` s en cance´rologie. Bull Acad Natle Méd 1997;<br />
181:139–162.<br />
140
Change language